The dopamine system is a primary treatment target for cocaine dependence (CD), but research on dopaminergic abnormalities (eg, D 2 receptor system deficiencies) has so far failed to translate into effective treatment strategies. The D 3 receptor system has recently attracted considerable clinical interest, and D 3 antagonism is now under investigation as a novel avenue for addiction treatment. The objective here was to evaluate the status and behavioral relevance of the D 3 receptor system in CD, using the positron emission tomography (PET) radiotracer [ 11 C]-( þ )-PHNO. Fifteen CD subjects (many actively using, but all abstinent 7-240 days on scan day) and fifteen matched healthy control (HC) subjects completed two PET scans: one with [
INTRODUCTION
Cocaine is among the most commonly abused illicit substances worldwide, with cocaine dependence (CD) contributing significantly to societal burdens such as health care, criminal justice, and public safety costs and lost productivity (Degenhardt and Hall, 2012) . Despite relatively high treatment-seeking rates and ongoing efforts to improve therapeutic approaches, however, clinical success rates remain low, and no pharmacotherapies have been approved to date (Haile et al, 2012) . A better understanding of neurobiological mechanisms contributing to CD could advance treatment strategies and improve clinical outcomes.
Among the main targets of investigation is the brain dopamine (DA) system, which not only is directly modulated by the acute action of cocaine, but also has a pivotal role in the addiction and withdrawal phenotypes (Melis et al, 2005) . Decades of preclinical research, now supported by human neuroimaging findings, suggest that DA transmission at D 2/3 receptors is diminished in addicted individuals abstinent X2 weeks (Melis et al, 2005) , with higher relapse risk in those with the lowest transmission Wang et al, 2012) . This evidence has prompted the view that low D 2 is a useful biomarker for relapse risk, and that increasing DA transmission to ameliorate a hypo-active DA system may improve treatment success; however, this approach has yet to prove clinically efficacious.
At the same time, a novel line of research focused on the D 3 DA receptor-a member of the D 2 -like family with unique features relevant to addiction )-points to D 3 as a potential new treatment target. The anatomical distribution of this receptor overlaps with key addiction neurocircuitry, including midbrain projections to limbic forebrain regions (amygdala, bed nucleus of stria terminalis, nucleus accumbens shell) mediating motivation, inhibitory control, emotion, and learning , which can modulate activity in cortical loops involved in motivation, salience attribution, conditioned responses, and compulsive behavior (Cole et al, 2012) . Moreover, preclinical studies demonstrate D 3 upregulation following dopaminergic drug regimens, with corresponding behavioral sensitization, increased motivation, and drug seeking (LeFoll et al, 2005; Sokoloff et al, 2001) . In line with these data, post-mortem human studies have reported elevated D 3 levels in striatum of cocaine overdose fatalities (Segal et al, 1997; Staley and Mash, 1996) , and neuroimaging findings from our laboratory point to similar effects in vivo, showing D 3 elevation in D 3 -rich regions (substantia nigra (SN), globus pallidus (GP), ventral pallidum (VP)) in methamphetamine dependence (MD), which (in SN) relates to drug wanting (Boileau et al, 2012b) . D 3 contributions may even generalize to behavioral addictions, as we have also reported a relationship between SN D 3 and symptom severity in pathological gambling (Boileau et al, 2012a) .
Importantly, D 3 receptor antagonists have shown promise in reversing acquisition and expression of drug-seeking and cue-induced relapse in animals (Heidbreder and Newman, 2010; Heidbreder et al, 2005) , and clinical trials of nicotine dependence and food reward are translating this idea to humans (Mugnaini et al, 2013; Nathan et al, 2012) . Taken together, the evidence suggests that activity at the D 3 receptor is pathologically increased in addiction (in contrast to D 2 downregulation), and, by extension, that a therapeutic strategy aimed at normalizing low transmission at D 2 may undermine clinical outcome by exacerbating alreadyexaggerated D 3 processes.
Positron emission tomography (PET) neuroimaging provides a non-invasive method to investigate DA receptors in human brain in vivo, but the evidence regarding D 3 is sparse, owing to a lack (until recently) of suitable radioligands. Most DA PET studies have used [ Wilson et al, 2005) ), on the other hand, is a recently developed D 2/3 radioligand with preferential affinity for D 3 in vivo, allowing for measurement of this receptor in D 3 -rich areas (whereas in D 3 -devoid regions, signal reflects D 2 ; Tziortzi et al, 2011). Using [ ]raclopride in the same individuals, therefore, allows for a more detailed understanding of dopaminergic targets for pharmacological strategies.
In a previous study using [ 11 C]-( þ )-PHNO, we reported higher D 3 receptor availability in the SN and marginally lower D 2/3 in the striatum of methamphetamine-dependent polydrug-abusing subjects compared with controls (Boileau et al, 2012b) . The present study, conducted in an independent sample of minimally comorbid cocaine-dependent subjects (many actively using, but all abstinent with negative urine screens on scan day), tested the hypothesis that [ 11 C]-( þ )-PHNO binding to D 3 would be elevated in CD and related to the addiction behavioral phenotype, whereas [ 11 C]raclopride binding was expected to be low.
MATERIALS AND METHODS

Subjects
All procedures were approved by the Centre for Addiction and Mental Health Research Ethics Board and complied with ethical standards of the Helsinki Declaration (1975; updated 1989) . Fifteen CD volunteers were recruited from a community program ('Getting Started,' an ambulatory twice-weekly psychoeducation and support program aimed at engaging clients and increasing readiness for intensive treatment, but itself providing no therapeutic intervention). For comparison, 15 healthy control (HC) volunteers were recruited from the community via flyers and advertisements. After complete description of the study, all volunteers gave written informed consent.
Subjects in the CD group were required to (1) self-report cocaine as the primary currently abused drug; (2) meet DSM-IV criteria for CD (as per SCID); and (3) provide a scalp hair sample and/or urine screen positive for cocaine/ metabolites. HC subjects were required to have no history of cocaine use, and no more than five lifetime occasions of recreational drug use (except cannabis). All subjects were required to be 18-55 years old and meet the following criteria: (1) no current Axis I disorder (as per SCID), except CD or substance-induced mood disorder in CD; (2) no lifetime history of alcohol or substance dependence (except caffeine or nicotine, and cocaine in CD; cannabis abuse was not exclusionary); (3) no medical conditions likely to affect the brain; (4) no current use of antidepressant or psychotropic medications; and (5) no PET or magnetic resonance image (MRI) contraindications (eg, radiation exposure exceeding guidelines, metal implants, pregnancy/ lactation).
Study Procedure and Outcome Measures
Screening session. Screening for inclusion/exclusion consisted of the SCID for DSM-IV, detailed medical history, and questionnaires assessing alcohol and drug use patterns and depressive symptomatology (Beck Depression Inventory (Beck and Steer, 1984 ), Snaith-Hamilton Pleasure Scale (Snaith et al, 1995) ). For CD subjects, we additionally assessed drug use history, severity, and toxicology (via scalp hair (US Drug Testing Laboratory) to assess drug use in recent months, and a comprehensive urine screen (9-Drug Test Panel, BTNX; broad spectrum, GC-MS) to test for prescription and illicit drugs.
Behavioral battery. Subjects underwent a brief battery of tests aimed at characterizing the CD behavioral phenotype. Tests included: the Halsted-Reitan Trail-Making Task (Reitan, 1955) to assess attention and set-shifting, Continuous Performance (Conners, 1994) and Go/No-Go tasks to assess attention and inhibitory control, the Balloon Analogue Risk Task (Lejuez et al, 2002) and Game of Dice Task (Brand et al, 2005) to assess risky decision making, the Kirby Delay Discounting Task (Kirby, 2000) to assess temporal discounting of reward, the Wisconsin Card Sorting Test to assess perseverative responding, the Barratt Impulsiveness Scale (Patton et al, 1995 ) and a Finger Tapping task to assess psychomotor function.
Neuroimaging session. Neuroimaging consisted of two PET scans, [ , along with a MRI to help delineate regions of interest (ROI) in PET analyses. CD subjects were not admitted to an inpatient unit for withdrawal management, but were asked to discontinue all drug use (except cigarette smoking) at least 10 days before the PET session. Compliance was assessed with a urine drug screen on scan day, requiring a negative result for cocaine. To avoid nicotine withdrawal on PET day, cigarette smokers were advised to smoke to satiation before each scan (up until 1 h before each injection). At the beginning of the PET day, CD subjects completed assessments of cocaine craving and withdrawal (Cocaine Selective Severity Assessment (Kampman et al, 1998) , Cocaine Urge Questionnaire (adapted from Bohn et al (1995) , Desire for Cocaine Scale (adapted from James et al (2004) ).
[
11 C]-( þ )-PHNO and [ 11 C]raclopride synthesis and image acquisition protocols are described in detail elsewhere (Graff-Guerrero et al, 2008) . PET scanning was performed on a high-resolution PET camera system (CPS-HRRT, Siemens Medical Imaging, Knoxville, TN), using a custom fitted thermoplastic mask to reduce head movement (TruScan Imaging, Annapolis, USA). Following a 15-min transmission scan, a bolus injection of [ (Ginovart et al, 2007) . The MRI (Signa 1.5T, General Electric Medical Systems, Milwaukee, WI) consisted of a standard proton density sequence acquired over the whole brain.
Image Analysis and Statistical Approach
Delineation of ROIs including whole striatum, sensorimotor striatum (SMST), associative striatum (AST), limbic striatum (LST), VP, GP, SN, and cerebellar cortex (excluding vermis and lobules IX and X) is described in Martinez et al (2003) and Boileau et al (2012b) . SN, VP, and GP ROIs were included because they are rich in D 3 and a high proportion of [ 11 C]-( þ )-PHNO signal (100%, 75%, and 65%, respectively) reflects D 3 binding (Tziortzi et al, 2011) .
11 C]raclopride time activity curves were obtained from dynamic data using ROMI (Rusjan et al, 2006) . Specific binding (BP ND ) in ROIs was estimated using the simplified reference tissue method (Lammertsma and Hume, 1996) , implemented in PMOD (v 2.8.5; PMOD Technologies Ltd, Zurich, Switzerland); this method is most suitable for simplified analysis, as it minimizes BP ND under-estimation and inter-individual variability (Ginovart et al, 2007) .
Group comparisons of [ ]raclopride BP ND were performed using repeated-measures ANOVAs or ANCOVAs (with ROIs as the repeated measure and CD vs HC as the between-groups factor), using Greenhouse-Geisser sphericity corrections when indicated. Regional group differences were examined for significance using t-tests, Bonferroni corrected for planned comparisons. Relationships between PET measures and continuous behavioral variables were analyzed with Pearson product moment correlations and Spearman's Rank tests for categorical data.
RESULTS
Subject Characteristics
Subject characteristics and demographic information are described in Table 1 . CD and HC groups were matched for age, sex, ethnicity, body mass, and cigarette and alcohol use, but CD subjects had lower education levels and consumed more cannabis. CD also reported more depressive symptomatology and anhedonia than HC, and two CD subjects met criteria for a current substance-induced depressive episode at study entry. Control analyses for these factors (see below) confirmed that they did not influence the results.
Cocaine use characteristics in the CD group are described in Table 2 . During the screening/intake session, 10 out of 15 CD provided a cocaine-positive urine test, confirming recent cocaine use, and hair analysis confirmed cocaine use in the remaining five subjects (and all other subjects with scalp hair, 12 out of 15). In a minority of the sample, toxicology screening (performed during the screening/intake session) also revealed (limited) use of other drugs: opiate metabolites in hair (3 out of 15) and urine (1 out of 15), cannabis in urine (4 out of 15), and benzodiazepine in hair (1 out of 15). Although subjects were asked to remain at least 10 days abstinent between screening and PET visits, two subjects only achieved 7 days abstinence between visits; however, their urine screens still met the requirement of testing negative for cocaine on scan day.
PET Results
All subjects completed both PET scans, but one CD Figure 1a ). Group differences were not statistically significant in other D 3 -rich regions (VP: þ 5%; GP: À 9%) or the striatum ( À 4 to 5%).
A second ANOVA investigating [ 11 C]raclopride BP ND found lower binding in CD than HC ( Figure 1b) ; this effect was not region dependent, but occurred in the striatum as a whole ( À 11%; F(1,27) ¼ 4.32, po0.05). Group differences were not statistically significant in individual striatal subdivisions (AST:
Several follow-up tests were performed to rule out potentially confounding factors. In all ROIs, PET measures (BP ND ) did not differ between CD subjects who did and did not (n ¼ 5) provide a cocaine-positive urine at study entry (indicating recent use vs abstinence; all p40.25), between those who did (n ¼ 4) and did not currently abuse cannabis (all p40.25), or between those who did (n ¼ 2) and did not experience current drug-induced depressive symptoms (all p40.1). Further, removing abstinent subjects and subjects co-morbid for cannabis/depression from analyses did not affect the ROI Â Group effect in 
Behavioral Battery and Relationships with PET Measures
As the behavioral battery was aimed at characterizing the CD phenotype, all CD subjects but not all HC subjects, completed the battery, so that group comparisons are not presented here (means are available in Supplementary  Table 1) . Across CD subjects, assessing correlations between [ 
DISCUSSION
The present study supports our predictions of high D 3 (compared with low D 2 ) receptor availability in CD. The findings add to a small but growing human neuroimaging literature pointing to D 3 as a novel biomarker and potential treatment target, and are also in line with the extensive body of research showing downregulation of D 2 . In addition to Tziortzi et al, 2011) . The pattern is reiterated in the D 3 -rich VP (where 75% of signal reflects D 3 ), but this difference was not statistically significant. Importantly, we also identified a relationship between SN [ 11 C]-( þ )-PHNO binding and impulsivity/risky decision making, suggesting that D 3 is relevant to behavioral contributors to addiction. The finding is consistent with post-mortem data showing elevated D 3 levels in cocaine abuse (Segal et al, 1997; Staley and Mash, 1996) , as well as a sizeable body of preclinical data, which, although not entirely consistent (Richtand et al, 2001 ), mainly demonstrates D 3 upregulation and related locomotor sensitization, drug cue reactivity, drugseeking, and motivation to take drugs (LeFoll et al, 2005; Sokoloff et al, 2001) . Our finding of 24% higher SN D 3 binding in CD vs HC is remarkably in line with a preliminary report that reported 22% greater [ (Matuskey et al, 2011) . It also echoes our previous neuroimaging studies of MD (Boileau et al, 2012b) , where we showed heightened SN [ (Boileau et al, 2012b ; 24% here vs 46% in MD), which could be explained by age differences between samples (mean 42 years here vs 28 years in MD), or differences between the two drugs (eg, mechanism of action, duration of effects, route of administration).
An interesting (although controversial) point is that in our previous report, we calculated relative D 3 levels, ie, individual D 3 -to-D 2 ratios estimated as [ (Tziortzi et al, 2011) ), and showed that this measure was greater in stimulant dependent than control subjects (Boileau et al, 2012b) . Here, too, we find that CD subjects had a 32% greater D 3 -to-D 2 binding fraction than HC (p ¼ 0.01), possibly providing further evidence for heightened D3 receptor expression (outside of SN). However, the biological relevance of this index is under debate, and the implications of this finding therefore highly speculative.
Together, [ 11 C]-( þ )-PHNO PET studies suggest that D 3 elevation may be a consistent and predictive biomarker for addiction, with potential use for clinical innovation. Indeed, the clinical utility of targeting D 3 in addiction treatment is currently under intensive investigation: Preclinical studies with highly selective D 3 receptor antagonists have observed attenuation of drug-seeking, self-administration, and cueand stress-induced reinstatement in animal models of addiction (Heidbreder and Newman, 2010; Heidbreder et al, 2005; LeFoll et al, 2007) , and in humans, clinical trials have reported D 3 antagonist effects on food reward and nicotine craving in smokers (Mugnaini et al, 2013 ; Mechanisms underlying the paradoxical upregulation of D 3 (contrasting with D 2 downregulation) and its downstream effects are still unclear (see Boileau et al (2012b) for discussion). Briefly, upregulation is thought to result from repeated stimulation of D 1 receptors during cocaine use, leading to release of brain-derived neurotrophic factor (BDNF), which is, in turn, linked to increased D 3 expression (Guillin et al, 2001) , and is elevated in CD (D'Sa et al, 2011) . Although D 3 receptors are expressed on all DA neurons in the SN, their physiological role there remains under debate (Davila et al, 2003) ; moreover, D 3 receptors are both reciprocal autoreceptors and heteroreceptors (Sokoloff et al, 1990) , and it is unknown whether the D 3 upregulation occurs on dopaminergic or other (eg, GABAergic) neurons (Bordet et al, 1997; Guillin et al, 2001) . Increased transmission at D 3 appears to modify limbic outputs and functional connectivity between orbitofrontal cortex and networks involved in cognitive control and goal-directed behavior (Cole et al, 2012) , thereby modulating motivation to use drugs. Future studies will be important in determining the effects of D 3 antagonism on these outcomes.
A secondary finding of the study is that [
11 C]raclopride binding in striatum was lower in CD than HC subjects, suggesting low D 2 availability (although [ 11 C]raclopride cannot distinguish between D 2 and D 3 ). This effect was statistically significant only when considering the striatum as a whole, but the 10-11% difference we observed in individual subregions is within the range of what has been previously reported ( À 6-17%; Martinez et al, 2004 Martinez et al, , 2011 Narendran et al, 2011) , and effect size estimates are in the medium range, suggesting that our failure to find significant group differences in individual subregions may have been due to low statistical power. The pattern of low D 2/3 signal is consistent with preclinical and other PET imaging evidence, supporting the notion that low D 2 availability is a hallmark of addiction across a range of substances, reflecting a hypodopaminergic state that can contribute to relapse to drug use Wang et al, 2012) . Our finding therefore confirms that our CD sample has comparable dopaminergic characteristics to previous study samples Wang et al, 2012) , suggesting that the D 3 finding reflects a previously unobserved process rather than sample differences.
One question raised by our use of two radiotracers is why low striatal D 2/3 levels were detected with [ (Bordet et al, 1997) and would mask lowered D 2 receptor binding. Alternatively, as an agonist radiotracer, [ 11 C]-( þ )-PHNO is more sensitive to endogenous DA levels (Shotbolt et al, 2012; Willeit et al, 2008) , so that low tonic DA levels in CD subjects could have led to more available receptor sites, masking lowered D 2 levels. Last, [ 11 C]-( þ )-PHNO only labels receptors in the G-protein-coupled high-affinity state (D 2HIGH ), and as animal literature suggests that D2 HIGH proportion is relevant to addiction (Seeman et al, 2007) , it is possible that our failure to detect group differences with [ Several limitations of the study should be noted. The first concerns the study sample, which included CD subjects with a wide range of abstinence durations (which was not supervised) and in some cases co-morbid drug use or mood symptoms. Our inclusion of 10 out of 15 actively using (albeit urine-negative) CD subjects distinguishes our studies from previous reports, which imposed a monitored/supervised abstinence period of at least 14 days (eg, Martinez et al, 2004 Martinez et al, , 2011 Wang et al, 2012) . We conducted explicit follow-up analyses to test for differences between actively using and abstinent subjects in our sample, and found no modulating effects of abstinence (or mood/ comorbid drug use), although these had low power and require confirmation in larger samples. At the same time, we excluded other co-morbidities to strengthen our ability to attribute effects to CD, limiting generalizability to the broader CD population. Another set of limitations concerns the radiotracer [
11 C]-( þ )-PHNO, including previously noted limitations (see Rabiner and Laruelle (2010) ) such as scanning at non-tracer doses (Shotbolt et al, 2012) , using a reference tissue with known specific binding (cerebellum (Murray et al, 1994) -although vermis and lobules 9 and 10 were excluded), and long wash-out times in D 3 -rich regions that may limit adequate quantification of receptor binding (Willeit et al, 2006) . In addition, as SN is the only region where 100% of [ 11 C]-( þ )-PHNO signal reflects D 3 binding, with all other ROIs reflecting some mixture of D 2 and D 3 (Tziortzi et al, 2011) , interpretation of findings is anatomically limited. Finally, as in all cross-sectional studies of drug abuse, we acknowledge that group differences could have predated drug use, and that longitudinal designs must be employed to distinguish cause and effect.
Despite these limitations, the present study is consistent with preclinical and post-mortem data, replicates our previous finding of heightened SN D 3 levels in psychostimulant addiction, and is the first to address the combination of D 3 and D 2 receptor states in CD. D 3 upregulation is emerging as a biomarker of the addicted state, and the newly gained ability to examine pharmacological features in living humans with [ 
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